The Drug Regulatory Authority of Pakistan (DRAP), on monday, has approved Phase III clinical trials of a corona virus vaccine developed by a Chinese company.
The Ministry of National Health Services Regulation and Coordination received a formal approval from the Drug Regulatory Authority of Pakistan (DRAP).
For a formal approval from DRAP for Phase III Clinical Trial of Recombinant Novel Corona virus Vaccine and Adenovirus Type 5 vector (Ad5-nCoV) developed by CanSinoBio and Beijing Institute of Biotechnology China [BIB] ,NIH stated:
“This is going to be the first ever phase III clinical trial for any vaccine in Pakistan.”
Around two hundred volunteers from Karachi, representing various ethnic groups, have already been registered for the clinical trials. It is expected to span a 56 days duration and three injections of the inactivated virus would be administered to the volunteers during this duration.
